Salivary Gland Tumor Cell Biorepository

唾液腺肿瘤是一种罕见的肿瘤，在美国每年约有3,300例新发病例。虽然手术是这些肿瘤的主要治疗方式，但晚期不可切除的原发性、复发性和转移性肿瘤通常是致命的。 值得注意的是，唾液腺恶性肿瘤的总体发病率与慢性粒细胞白血病（CML）相似，但联邦和私人CML研究企业远远超过唾液腺肿瘤。因此，在实地工作的调查人员相对较少，调查人员从事这类研究所需的大量研究工具尚未建立。 2006年10月，NCI和NIDCR召开了关于恶性涎腺肿瘤生物学和治疗的第一次研讨会。 得出的结论是，这一领域在各个方面都缺乏进展，从基础生物学到治疗和病人管理。 更重要的是，研讨会揭示了缺乏组织标本，细胞系和动物模型等研究工具，这些工具有助于促进该领域的基础和转化研究。 此外，还没有集中努力对这些资源进行编目和收集，以提供给校外社区。 为了推进这一领域的基础和转化研究，并最终改善公众健康，NIDCR领导了支持在一个具有头颈部和唾液腺肿瘤生物学和病理学专业知识的学术机构建立集中生物储存库的努力。NIDCR确定了MDACC的阿德尔El-Naggar博士，他是国内和国际公认的唾液腺肿瘤生物学和病理学专家，来领导集中式生物储存库。El-Naggar博士通过同意向生物储存库提供生物标本的卫星中心联盟，协调了在MDACC建立集中生物储存库的工作。 他确定了一些唾液腺病理学和生物学方面的核心专家，他们可以帮助识别和分类与诊断，病理，治疗和结果数据相关的生物标本。 通过该联盟，生物储存库存储和编目新鲜冷冻的唾液腺肿瘤组织和石蜡块（如适用，与匹配的血清，唾液，淋巴细胞）以及相关的临床数据。 预计将通过一个可在线搜索的网上电子界面，便利获取关于生物标本和相关临床数据的信息。

Salivary gland tumors are rare neoplasms with approximately 3,300 new cases per year in the US. While surgery is the main modality of treatment for these tumors, advanced unresectable primary, recurrent and metastatic tumors are generally fatal. It is important to note that the overall incidence for salivary gland malignancies mimics those of chronic myelocytic leukemias (CML), yet federal and private research enterprises for CML far exceed those for the salivary gland tumors. As a result, there have been relatively few investigators working in the field and a critical mass of research tools for investigators to engage in this type of research has not been established. In October 2006, NCI and NIDCR convened the first workshop on the ¿Biology and Treatment of Malignant Salivary Gland Tumors.¿ It was concluded that this field is suffering from lack of progress in all aspects, from basic biology to therapy and patient management. More importantly, the workshop revealed that there is a paucity of research tools such as tissue specimens, cell lines, and animal models that are instrumental in promoting the basic and translational research in the field. Furthermore, a centralized effort to catalogue and collect these resources that can be made available to the extramural community is lacking. In an effort to advance basic and translational research in this field and ultimately improve public health, NIDCR led the effort to support the establishment of a centralized biorepository at an academic institution with known expertise in head and neck and salivary gland tumor biology and pathology NIDCR identified Dr. Adel El-Naggar at MDACC, a nationally and internationally recognized expert in salivary gland tumor biology and pathology, to lead the centralized biorepository. Dr. El-Naggar coordinated the effort to establish a centralized biorepository at MDACC through a consortium of satellite centers that agreed to contribute biospecimens to the biorepository. He identified a core number of experts in salivary gland pathology and biology who could help identify and catalogue biospecimens linked to diagnostic, pathologic, treatment, and outcome data. Through this consortium, the biorepository stores and catalogues fresh frozen salivary gland tumor tissues and paraffin blocks (with matched serum, saliva, lymphocytes, if applicable), as well as associated clinical data. It is anticipated that access to information on biospecimens and associated clinical data will be facilitated through a web-based electronic interface that is searchable online.